GlaxoSmithKline Common Stock Total Equity vs Cash Analysis

GSK Stock  USD 33.70  0.35  1.05%   
GlaxoSmithKline PLC financial indicator trend analysis is much more than just examining GlaxoSmithKline PLC ADR latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether GlaxoSmithKline PLC ADR is a good investment. Please check the relationship between GlaxoSmithKline PLC Common Stock Total Equity and its Cash accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlaxoSmithKline PLC ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

Common Stock Total Equity vs Cash

Common Stock Total Equity vs Cash Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of GlaxoSmithKline PLC ADR Common Stock Total Equity account and Cash. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between GlaxoSmithKline PLC's Common Stock Total Equity and Cash is -0.24. Overlapping area represents the amount of variation of Common Stock Total Equity that can explain the historical movement of Cash in the same time period over historical financial statements of GlaxoSmithKline PLC ADR, assuming nothing else is changed. The correlation between historical values of GlaxoSmithKline PLC's Common Stock Total Equity and Cash is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Common Stock Total Equity of GlaxoSmithKline PLC ADR are associated (or correlated) with its Cash. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cash has no effect on the direction of Common Stock Total Equity i.e., GlaxoSmithKline PLC's Common Stock Total Equity and Cash go up and down completely randomly.

Correlation Coefficient

-0.24
Relationship DirectionNegative 
Relationship StrengthInsignificant

Common Stock Total Equity

The total value of common stock equity held by shareholders, representing their ownership interest in the company.

Cash

Cash refers to the most liquid asset of GlaxoSmithKline PLC ADR, which is listed under current asset account on GlaxoSmithKline PLC ADR balance sheet and usually includes currency, coins, checking accounts, and not deposited checks received from GlaxoSmithKline PLC customers. The amounts must be unrestricted with restricted cash listed in a different GlaxoSmithKline PLC account. The total amount of money in the form of currency that a company has in its possession. This includes all bills, coins, and funds in bank accounts.
Most indicators from GlaxoSmithKline PLC's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into GlaxoSmithKline PLC ADR current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlaxoSmithKline PLC ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
At this time, GlaxoSmithKline PLC's Selling General Administrative is quite stable compared to the past year. Discontinued Operations is expected to rise to about 12.7 B this year, although Enterprise Value Over EBITDA will most likely fall to 7.68.
 2021 2022 2023 2024 (projected)
Interest Expense784M879M775M502.2M
Depreciation And Amortization2.1B2.1B2.3B2.4B

GlaxoSmithKline PLC fundamental ratios Correlations

0.920.220.890.50.890.90.330.610.990.060.590.220.29-0.020.950.950.50.970.320.910.70.710.70.110.94
0.920.090.830.410.880.980.410.650.9-0.050.550.020.28-0.060.910.90.610.910.230.870.730.870.730.020.82
0.220.090.090.780.130.05-0.620.190.170.580.550.780.270.370.050.16-0.30.070.490.370.33-0.20.330.680.13
0.890.830.090.30.890.830.530.450.870.170.530.160.290.10.830.940.540.940.360.870.710.720.71-0.070.77
0.50.410.780.30.270.43-0.440.190.490.540.440.770.570.20.290.35-0.260.310.560.480.330.250.330.880.51
0.890.880.130.890.270.830.560.740.840.070.66-0.020.33-0.10.910.970.770.940.430.930.920.710.92-0.20.73
0.90.980.050.830.430.830.380.50.890.010.460.080.31-0.010.870.870.540.890.240.820.650.90.650.070.82
0.330.41-0.620.53-0.440.560.380.330.33-0.280.0-0.610.11-0.330.440.480.780.50.040.30.430.490.43-0.710.3
0.610.650.190.450.190.740.50.330.56-0.290.71-0.240.03-0.240.680.640.640.610.080.720.770.370.77-0.190.48
0.990.90.170.870.490.840.890.330.560.020.50.220.26-0.070.940.920.450.950.280.850.630.70.630.130.97
0.06-0.050.580.170.540.070.01-0.28-0.290.020.30.760.710.5-0.050.11-0.20.040.830.220.2-0.020.20.49-0.01
0.590.550.550.530.440.660.460.00.710.50.30.250.260.430.560.640.390.570.340.840.750.310.750.110.35
0.220.020.780.160.77-0.020.08-0.61-0.240.220.760.250.380.440.030.11-0.520.080.570.20.01-0.120.010.780.25
0.290.280.270.290.570.330.310.110.030.260.710.260.380.020.20.310.150.250.840.360.420.350.420.410.27
-0.02-0.060.370.10.2-0.1-0.01-0.33-0.24-0.070.50.430.440.02-0.1-0.03-0.26-0.020.020.17-0.030.0-0.030.24-0.14
0.950.910.050.830.290.910.870.440.680.94-0.050.560.030.2-0.10.940.670.970.250.870.710.710.71-0.130.88
0.950.90.160.940.350.970.870.480.640.920.110.640.110.31-0.030.940.660.980.40.940.820.70.82-0.080.82
0.50.61-0.30.54-0.260.770.540.780.640.45-0.20.39-0.520.15-0.260.670.660.640.160.580.720.530.72-0.660.35
0.970.910.070.940.310.940.890.50.610.950.040.570.080.25-0.020.970.980.640.310.910.740.750.74-0.110.88
0.320.230.490.360.560.430.240.040.080.280.830.340.570.840.020.250.40.160.310.430.540.180.540.320.26
0.910.870.370.870.480.930.820.30.720.850.220.840.20.360.170.870.940.580.910.430.880.650.880.050.72
0.70.730.330.710.330.920.650.430.770.630.20.750.010.42-0.030.710.820.720.740.540.880.551.0-0.130.49
0.710.87-0.20.720.250.710.90.490.370.7-0.020.31-0.120.350.00.710.70.530.750.180.650.550.55-0.040.65
0.70.730.330.710.330.920.650.430.770.630.20.750.010.42-0.030.710.820.720.740.540.881.00.55-0.130.49
0.110.020.68-0.070.88-0.20.07-0.71-0.190.130.490.110.780.410.24-0.13-0.08-0.66-0.110.320.05-0.13-0.04-0.130.2
0.940.820.130.770.510.730.820.30.480.97-0.010.350.250.27-0.140.880.820.350.880.260.720.490.650.490.2
Click cells to compare fundamentals

GlaxoSmithKline PLC Account Relationship Matchups

GlaxoSmithKline PLC fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets79.7B80.4B79.1B60.1B59.0B32.8B
Short Long Term Debt Total30.5B27.2B24.2B21.0B18.0B11.0B
Other Current Liab755M13.5B15.0B14.5B13.8B14.5B
Total Current Liabilities24.1B22.1B23.7B22.8B21.1B11.2B
Total Stockholder Equity12.0B14.6B15.1B10.6B13.3B14.0B
Property Plant And Equipment Net11.3B11.0B10.7B9.6B10.0B7.2B
Net Debt25.8B20.9B19.9B17.3B15.1B8.3B
Accounts Payable14.9B4.4B4.5B3.9B3.7B5.1B
Cash4.7B6.3B4.3B3.7B2.9B2.7B
Non Current Assets Total60.2B60.2B60.4B39.4B40.4B20.9B
Non Currrent Assets Other1.2B1.1B1.8B5.3B7.2B7.5B
Cash And Short Term Investments4.8B6.4B4.3B7.9B5.7B4.0B
Common Stock Shares Outstanding4.0B2.0B1.6B2.0B4.1B4.3B
Liabilities And Stockholders Equity79.7B80.4B79.1B60.1B59.0B32.8B
Non Current Liabilities Total37.3B37.5B34.1B27.2B25.1B14.3B
Inventory5.9B6.0B5.8B5.1B5.5B3.0B
Other Stockholder Equity4.9B3.3B3.3B3.4B3.5B2.8B
Total Liab61.3B59.6B57.8B50.1B46.2B25.5B
Property Plant And Equipment Gross10.3B11.0B10.7B9.6B20.2B21.2B
Total Current Assets19.5B20.2B18.7B20.8B18.6B11.9B
Capital Stock1.3B1.3B1.3B1.3B1.3B1.3B
Short Term Debt6.9B3.7B3.6B4.0B2.8B2.2B
Common Stock1.3B1.3B1.3B1.3B1.3B1.3B
Retained Earnings5.1B6.8B7.9B4.4B7.7B8.1B
Accumulated Other Comprehensive Income641M1.6B642M(48M)805M845.3M
Intangible Assets31.0B29.8B30.1B14.3B14.8B11.4B
Other Liab13.7B14.1B13.5B10.2B11.7B14.2B
Long Term Debt22.6B23.4B20.6B17.0B14.2B17.5B
Good Will10.6B10.6B10.6B7.0B6.8B5.3B
Other Current Assets1.6B1.9B1.7B1.4B1.6B1.5B
Property Plant Equipment11.3B11.0B10.7B9.6B8.7B9.7B
Current Deferred Revenue1.4B1.8B1.6B299M222M233.1M
Other Assets5.1B5.3B6.9B6.9B7.9B5.4B
Net Receivables7.1B5.5B6.2B5.5B5.9B6.1B
Net Tangible Assets(30.1B)(25.8B)(25.6B)(10.8B)(12.4B)(13.0B)
Short Long Term Debt6.7B3.5B3.4B3.8B2.7B4.3B

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether GlaxoSmithKline PLC ADR is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if GlaxoSmithKline Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Glaxosmithkline Plc Adr Stock. Highlighted below are key reports to facilitate an investment decision about Glaxosmithkline Plc Adr Stock:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlaxoSmithKline PLC ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlaxoSmithKline PLC. If investors know GlaxoSmithKline will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlaxoSmithKline PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.28)
Dividend Share
0.61
Earnings Share
1.54
Revenue Per Share
15.38
Quarterly Revenue Growth
(0.02)
The market value of GlaxoSmithKline PLC ADR is measured differently than its book value, which is the value of GlaxoSmithKline that is recorded on the company's balance sheet. Investors also form their own opinion of GlaxoSmithKline PLC's value that differs from its market value or its book value, called intrinsic value, which is GlaxoSmithKline PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlaxoSmithKline PLC's market value can be influenced by many factors that don't directly affect GlaxoSmithKline PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GlaxoSmithKline PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if GlaxoSmithKline PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlaxoSmithKline PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.